Skip to main content
Premium Trial:

Request an Annual Quote

HGS Completes Phase I Study of Its Second Genome-Based Drug

Premium

ROCKVILLE, Md.--Human Genome Sciences announced last week that it successfully completed phase I clinical studies of its second genomics-derived drug. Keratinocyte growth factor-2 (KGF-2) is a therapeutic protein being evaluated as a treatment for wound-healing. Successful phase I studies of Myeloid progenitor inhibitory factor-1 were announced last month. The drugs are the first two therapeutic products discovered using genomic techniques to enter clinical trials, the company claimed. CEO William Haseltine said HGS could now be called "a pioneer in genomic drug development as well as in genomics."

Filed under

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.